Potent hypervalent nanoparticles against HIV, Lassa and SARS-CoV-2 variants HIV Nanoparticles LassaVirus SARS SARSCoV2 Coronavirus Disease COVID advscinews
Study: Rational Development of Hypervalent Glycan Shield-Binding Nanoparticles with Broad-Spectrum Inhibition against Fatal Viruses Including SARS-CoV-2 Variants. Image Credit: Kateryna Kon / Shutterstock
Molecularly-imprinted polymers , also known as plastic/artificial antibodies, are synthetic receptors with antibodies that mimic antibody binding through copolymerization in the presence of templates. Due to ease of preparation, storage stability, and cost efficiency, MIPs exhibit potential for different applications such as diagnosis, cancer therapy, virus recognition, and toxin neutralization. MIPs have been developed against viruses, but none with broad-spectrum activity.
The authors next studied the binding and kinetics of nanoMIPs to proteins with high-mannose glycans using biolayer interferometry. First, RNase B was used as the target protein, and the dissociation constant was 1.3 x 10-6 M, two-to-three orders of magnitude improved relative to the Kd of mannose. The Kd for SARS-CoV-2 S1 protein was 5.3 x 10-7 M. In contrast, NIPs did not bind to RNase or SARS-CoV-2 S1.
Potent inhibition of live viruses. a,b) The authentic SARS-CoV-2 virus RNA load at 3 days post-infection from Vero cells treated with different concentrations of nanoMIP. Mean ± SD, n = 3. c–f) Cytopathic effect images of Vero cells treated with nanoMIP , NIP , and MBL under the infection of live SARS-CoV-2 for 3 days.
Belgique Dernières Nouvelles, Belgique Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
What is the association between particulate matter exposure and SARS-CoV-2 infections?In a new study, researchers assessed the association between particulate matter ≤2.5mm (PM2.5) exposure and SARS-CoV-2 infection and severity outcomes such as hospitalizations and deaths.
Lire la suite »
Chitin-immobilized nanobodies for SARS-CoV-2 detectionChitin-immobilized nanobodies for SARS-CoV-2 detection medrxivpreprint HHU_de SARSCoV2 covid coronavirus COVID19 nanobodies
Lire la suite »
New method for isolating Omicron subvariant and evaluating resistance to therapeutic and vaccine-elicited antibodiesNew method for isolating Omicron subvariant and evaluating resistance to therapeutic and vaccine-elicited antibodies biorxivpreprint institutpasteur Omicron SARSCoV2 COVID19 Isolation Subvariant Antibodies
Lire la suite »
Additional mRNA COVID vaccine doses could salvage antibody responses in blood cancer patientsAdditional mRNA COVID vaccine doses could salvage antibody responses in blood cancer patients Antibody Blood BloodCancer Cancer Coronavirus Disease COVID Vaccine NatureComms imperialcollege
Lire la suite »
These Are The Autumn Wedding Guest Dresses You’ll Want To Wear Again And AgainWedding season rumbles on so here are the best autumn wedding guest dresses to shop now if you're in need of some inspo. Read more on Grazia.
Lire la suite »
CoviRx: A User-Friendly Interface for Systematic Down-Selection of Repurposed Drug Candidates for COVID-19Although various vaccines are now commercially available, they have not been able to stop the spread of COVID-19 infection completely. An excellent strategy to get safe, effective, and affordable COVID-19 treatments quickly is to repurpose drugs that are already approved for other diseases. The process of developing an accurate and standardized drug repurposing dataset requires considerable resources and expertise due to numerous commercially available drugs that could be potentially used to address the SARS-CoV-2 infection. To address this bottleneck, we created the CoviRx.org platform. CoviRx is a user-friendly interface that allows analysis and filtering of large quantities of data, which is onerous to curate manually for COVID-19 drug repurposing. Through CoviRx, the curated data have been made open source to help combat the ongoing pandemic and encourage users to submit their findings on the drugs they have evaluated, in a uniform format that can be validated and checked for integrity by authenticated volunteers. This article discusses the various features of CoviRx, its design principles, and how its functionality is independent of the data it displays. Thus, in the future, this platform can be extended to include any other disease beyond COVID-19.
Lire la suite »